Maze Therapeutics (MAZE) announced the appointment of Misbah Tahir as chief financial officer, CFO, effective immediately. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceutical industry. He most recently served as CFO of IGM Biosciences.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics initiated with a Buy at BTIG
- Maze Therapeutics’ MZE782: Promising Potential in CKD Treatment Through SLC6A19 Inhibition
- Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health
- Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
- Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782